Replimune's Drug Faces Third FDA Approval Attempt Amid Pfizer's New Deal in China
Replimune is set to make a third attempt for FDA approval of its drug, while Pfizer has recently secured a deal in China, highlighting ongoing developments in the pharmaceutical sector.
Editorial Staff 28 days ago